entertainment -WSS

entertainment

author：leisure time 2025-10-01 17:21:12 - browse：154

What makes a blockbuster? Can biotech learn from Aduhelm? And how do you replace a singular regulator?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We explain the debate over Vertex Pharmaceuticals’ novel pain drug, whose success in clinical trials comes with a sizable caveat. We also talk about the latest news in the life sciences, including an epitaph for Aduhelm and the retirement of an FDA icon.

For more on what we cover, here’s the news on Vertex; here’s more on Aduhelm; here’s the exit interview with Janet Woodcock; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： A new drug could help frostbite victims avoid its ravages

explore

WSS

Congress may force more Covid

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Hospitals are piloting generative AI tools as regulators play catch

Researchers tackle phage therapy hurdles for wider adoption

Flagship Pioneering startup Sonata Therapeutics lays off 21

hotspot

entertainment

entertainment

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Abridge raises $150m as clinical notes automation market heats up

Trump demands the U.S. pay no more for drugs than other countries … again

Medicare Advantage enrollment hits roughly 33.4 million

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

As AI regulations shape up, health tech startups beg for clarity

Trump demands the U.S. pay no more for drugs than other countries … again

New CMS data security rules will hurt Medicare, Medicaid research

What does generative AI mean for health care? We asked experts

The Readout: Amylyx, Alumis, and Lundbeck drug updates

explore

Former medical device CEO who sold dummy, plastic parts convicted of fraud

New study raises questions about niacin and heart health

MD Anderson's Padmanee Sharma responds to research credit suit

The drug industry has found itself all alone in Washington

NEJM study link tiny plastics in blood vessels to heart problems

The problem with charging patients to message their doctors

hotspot

explore

hotspot

leisure time